This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

COX-1 Vs COX-2 inhibitors (relative risk of GI side effects)

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

  • there is evidence that the use of COX-2 inhibitors leads to a reduced incidence of dyspepsia by 2% to 3% (1)

  • the frequency of potentially serious gastrointestinal complications (e.g. bleeding or perforation) is approximately 1% with conventional NSAID treatment - the use of COX-2 inhibitors seems to lower this risk by 0.5.% to 1% (1)
    • this evidence means that 100 to 200 "typical" patients need to be treated (NNT) with a COX-2 inhibitor rather than a conventional NSAID to prevent one serious gastro-intestinal complication. In patients at low risk of gastrointestinal complications, the NNT to prevent a serious complication may be about 500 (2)

  • a MeReC review stated that (3)
    • cox-2 inhibitors, as a class, are associated with a lower GI risk than traditional NSAIDs. However, their GI-safety advantage is diminished when co-administered with aspirin
    • of the traditional NSAIDS, low-dose ibuprofen is associated with a lower GI risk than diclofenac and naproxen
    • use of a proton pump inhibitor (PPI) with any NSAID significantly reduces the risk of GI side effects
    • benefits from gastroprotection largely depend on the baseline risk that the individual has for GI complications. There is, as yet, very little direct evidence that adding a PPI to a cox-2 inhibitor is more beneficial than adding a PPI to a traditional NSAID


  • (1) Henry D, McGettigan P.Commentary on "Rofecoxib caused fewer endoscopic gastroduodenal ulcers than ibuprofen in osteoarthritis". Evidence Based Medicine 2000 May-June, 5 (3), 74. Comment on: Laine L, Harper S, Simon T et al, for the Rofecoxib Osteoarthritis Endoscopy Study Group. A randomized trial comparing the effect of rofecoxib, a cyclo-oxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Gastroenterology 1999; 117: 776-83.
  • (2) Emery P, Seidler H, Kvien TK et al. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. Lancet 1999;354; 2106-11.
  • (3) MeReC Extra 2007;30.

Related pages

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.


Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.